Oncology Therapeutic Drug Monitoring Market size is valued at USD x million in 2021 and is expected to reach a value of USD x million by 2028, growing at a CAGR of x% during the forecast period 2022 to 2028. The global market provides a detailed overview of the Oncology Therapeutic Drug Monitoring Market and that can be segmented by monoclonal antibody type, and technology type. By monoclonal antibody type, the Oncology Therapeutic Drug Monitoring Market has been segmented into infliximab (IFX), adalimumab (ADL), vedolizumab (VDL), ustekinumab (UTK), golimumab (GLM), Etanercept (ETN), rituximab (RTX), tocilizumab (TCZ)). The golimumab (GLM)segment is likely to be the largest and fastest-growing segment in terms of monoclonal antibody type. Based on technology type, the Oncology Therapeutic Drug Monitoring Market is segmented into immunoassay and others. Among these, the immunoassay segment is expected to have the fastest-growing market during the forecast period 2022-2028.
In July 2021, Roche announced the approval of “Ronapreve” (casirivimab and indevimab) for intravenous infusion treatment of patients with mild to moderate COVID-19. Under Article 14-3 of the Pharmaceuticals and Medical Devices Act, the antibody combination received Special Approval.